Extract
Interstitial lung disease (ILD) refers to a large and heterogeneous group of parenchymal lung disorders [1], some related to other diseases such as connective tissue diseases (CTDs), some related to environmental exposures such as hypersensitivity pneumonitis, and others with an unknown cause and no identified aetiologic context. Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic ILD, the most severe of the chronic forms of ILDs and represents, by definition, the prototype of progressive fibrosing ILD characterised by decline in lung function and early mortality [2].
Abstract
Fibrosing ILDs can develop a progressive phenotype and are described under the terminology PF-ILDs. Due to commonalities with IPF, the potential efficacy and tolerability of antifibrotic drugs pirfenidone and nintedanib are currently evaluated in PF-ILDs. http://bit.ly/2koL0A4
Footnotes
Provenance: Commissioned article, peer reviewed.
Conflict of interest: V. Cottin reports personal fees and non-financial support from Actelion, grants, personal fees and non-financial support from Boehringer Ingelheim and Roche, and personal fees from Bayer/MSD, Gilead, Novartis, Sanofi, Promedior, Celgene, Galapagos and Galecto, outside the submitted work.
- Received August 19, 2019.
- Accepted September 13, 2019.
- Copyright ©ERS 2019.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.